Simcere Pharmaceutical Group Limited (FRA:S2P)

Germany flag Germany · Delayed Price · Currency is EUR
1.310
-0.020 (-1.50%)
Last updated: Apr 23, 2026, 9:07 AM CET
Market Cap3.54B +49.9%
Revenue (ttm)941.44M +16.5%
Net Income163.66M +83.3%
EPS0.07 +86.2%
Shares Outn/a
PE Ratio21.63
Forward PE17.92
Dividend0.02 (1.48%)
Ex-Dividend DateJun 18, 2025
Volume12,000
Average Volume600
Open1.310
Previous Close1.330
Day's Range1.310 - 1.310
52-Week Range0.945 - 1.600
Betan/a
RSI42.24
Earnings DateMar 25, 2026

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 7,038
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol S2P

Financial Performance

In 2025, FRA:S2P's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 83.32%.

Financial numbers in CNY Financial Statements